Key result
Metabolic stroke phenotype linked to ~51% lower odds of favorable 3-month functional outcome.
Why the study?
The biological determinants of heterogeneity in functional outcomes after endovascular thrombectomy remain poorly characterized.
Do biologically distinct phenotypes derived from post-procedural clinical and laboratory indicators predict 3-month functional outcome in patients undergoing endovascular thrombectomy for acute ischemic stroke?
Cohort (n=1,036)
No
Do biologically distinct phenotypes derived from post-procedural clinical and laboratory indicators predict 3-month functional outcome in patients undergoing endovascular thrombectomy for acute ischemic stroke?
Odds Ratio: 0.49 (95% CI 0.35–0.69)
Absolute Event Rate: 44.9% vs 70.8%
p-value: p=<0.001
Latent class analysis identifies three distinct biological phenotypes (low-burden, metabolic, and hypercoagulable) among patients undergoing EVT for acute ischemic stroke, which are independently predictive of divergent 3-month functional outcomes.
Metabolic and hypercoagulable phenotypes after thrombectomy were associated with worse outcomes; hypothesis-generating for risk stratification pending prospective validation.
Background Despite successful vascular recanalization, approximately half of patients undergoing endovascular thrombectomy (EVT) fail to achieve functional independence at 3 months. The biological determinants of this heterogeneity remain poorly characterized. Methods Latent class analysis (LCA) was applied to 825 consecutive EVT-treated patients (development cohort, January 2021–December 2024) using 12 routine post-procedural clinical and laboratory indicators. Phenotype associations with favorable 3-month outcome (modified Rankin Scale 0–2) were assessed using multivariable logistic regression. Reproducibility was evaluated in an independent temporal validation cohort ( n = 211). Results LCA identified three phenotypes. The Low-burden phenotype (Class 1, 44.4%) had the lowest inflammatory and coagulatory burden and achieved favorable outcome in 70.8% of patients. The Metabolic phenotype (Class 2, 42.7%), characterized by hyperglycemia and elevated neutrophil-to-lymphocyte ratio, had a favorable outcome rate of 44.9% and symptomatic intracranial hemorrhage (sICH) rate of 7.1%. The hypercoagulable phenotype (Class 3, 13.0%), defined by markedly elevated D-dimer and atrial fibrillation, had a favorable outcome rate of 40.2% and sICH rate of 8.4%. After multivariable adjustment, both Class 2 (OR 0.49, 95% CI 0.35–0.69) and Class 3 (OR 0.41, 95% CI 0.25–0.67) were independently associated with unfavorable outcome (both p < 0.001). Class distribution and outcome associations were reproduced in the validation cohort. Conclusion LCA identified three biologically distinct phenotypes among EVT-treated patients with divergent functional outcomes. Multicenter prospective validation is needed before these findings can inform clinical practice.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) conducted a cohort in Acute ischemic stroke undergoing endovascular thrombectomy (n=1,036). Metabolic phenotype (Class 2) and Hypercoagulable phenotype (Class 3) vs. Low-burden phenotype (Class 1) was evaluated on Favorable functional outcome (mRS 0-2) at 3 months (OR 0.49, 95% CI 0.35-0.69, p=<0.001). The Metabolic (Class 2) and Hypercoagulable (Class 3) phenotypes were independently associated with reduced odds of favorable 3-month outcomes compared to the Low-burden phenotype (OR 0.49 and 0.41).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: